CLIA Waived Drug Tests with Fentanyl: The Clinical Standard for Pain Management, Addiction Treatment, and Point-of-Care Fentanyl Screening: The CLIA Waived drug test with fentanyl range at 12 Panel Now is built for healthcare settings that require more than a presumptive forensic screen. Every product carries CLIA Waived certification and FDA approval, and every product includes fentanyl detection as a dedicated panel. The defining clinical advantage across this entire range is fentanyl detection at 1 ng/mL, the most sensitive threshold available in a point-of-care device, allowing clinical staff to identify fentanyl at concentrations that a standard 10 or 20 ng/mL FUO screen would miss entirely. At 12 Panel Now, every CLIA waived fentanyl drug test ships same day from our US-based warehouse with free shipping on qualifying bulk orders.

• Fentanyl at 1 ng/mL: The Most Sensitive Point-of-Care Fentanyl Cutoff Available: The standard fentanyl cutoff in non-CLIA oral swab and urine FUO devices is 10 to 20 ng/mL. Every multi-panel cup and dip card in the CLIA waived fentanyl range detects fentanyl at 1 ng/mL, ten to twenty times more sensitive than standard FUO screening. The FentaScan fluorescence analyzer adds 100% specificity at the same 1 ng/mL threshold, eliminating false positives while maintaining maximum sensitivity. For pain clinics monitoring prescription fentanyl compliance, and for addiction treatment programs screening for illicit fentanyl exposure in MAT populations, this sensitivity difference is not incremental — it is the difference between detecting clinically relevant fentanyl concentrations and missing them.
• CLIA Waived and FDA Approved: Results That Support Clinical Decision-Making: Every product in this range carries both CLIA Waived certification and FDA 510(k) approval, meeting the two federal regulatory standards required for point-of-care drug testing in clinical settings. CLIA Waived certification permits licensed healthcare providers to act on results without sending specimens to an external laboratory. FDA approval confirms the device meets federal accuracy and reliability standards. For programs billing under clinical drug testing CPT codes, operating in federally regulated healthcare environments, or documenting results in patient medical records, these certifications are mandatory requirements. Standard FUO drug tests do not carry these certifications and cannot be used for clinical documentation.
• The FentaScan Analyzer: Fluorescence-Based Fentanyl Detection with a Free Reader Device: The FentaScan CLIA Waived Fentanyl Cartridge uses fluorescence signal technology to detect fentanyl at 1 ng/mL with 100% specificity. Unlike lateral flow immunoassay strips, the fluorescence method eliminates the visual interpretation variability that can affect line-based results at very low concentrations. The system comes with a free FentaScan analyzer device on qualifying orders. For pain clinics and addiction programs that run high daily fentanyl test volumes, the analyzer-based format provides an objective, reader-independent result that supports documentation requirements and reduces clinician interpretation burden.
• EDDP Panel: The Methadone Metabolite That Standard MTD Strips Miss: The 14 panel CLIA waived cup adds EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine), the primary urinary metabolite of methadone, as a dedicated panel alongside the MTD parent compound. EDDP persists in urine for 3 to 4 days and is resistant to specimen dilution attempts, making it a more reliable compliance marker than the MTD parent compound in populations where specimen adulteration is a documented risk. For methadone maintenance clinics running compliance monitoring, EDDP detection alongside MTD provides two independent verification points from a single cup collection.
• Norfentanyl at 5 ng/mL: Extended Fentanyl Detection Window in the 15 Panel Cup: The 15 panel CLIA waived cup includes both FEN at 1 ng/mL and Norfentanyl (NFYL) at 5 ng/mL. Norfentanyl is the primary urinary metabolite of fentanyl and persists in urine for 24 to 72 hours after the parent compound has cleared. For programs where fentanyl exposure documentation needs to cover a longer post-use window than the parent compound alone provides, the combined FEN and NFYL detection in a single cup gives the most complete fentanyl exposure picture available in a point-of-care urine test.
• Multiple Device Formats: Cups, Dip Cards, Strips, and Analyzer for Every Clinical Setting: The CLIA waived fentanyl range includes four distinct device formats to match any clinical workflow. Integrated urine cups with built-in temperature strips and leak-proof lids are the most complete single-device format for point-of-care clinical collection. Multi-panel dip cards offer a portable slim-profile alternative with photocopy-compatible result windows for documentation. Single-panel fentanyl strips provide the lowest-cost add-on fentanyl screen for programs that already run multi-panel cups without FEN. The FentaScan fluorescence analyzer is the highest-specificity standalone fentanyl detection system for high-volume clinical fentanyl monitoring programs.
• Built-In Temperature Strip on All Cups: Specimen Integrity Verification at Point of Collection: Every integrated urine cup in the CLIA waived fentanyl range includes a built-in temperature strip that confirms the specimen is within the expected body temperature range at the time of collection. Specimen temperature outside the expected range is a documented indicator of substitution or adulteration. For clinical programs where specimen integrity documentation is part of the patient record or billing audit trail, the temperature strip provides a built-in validity check that requires no additional equipment or secondary test.
• 5-Minute Results with Over 99% Accuracy: Fast Enough for High-Volume Clinical Workflows: All multi-panel cups and dip cards deliver results within 5 minutes of specimen collection. The FentaScan analyzer reads in 5 minutes. Results are clear and easy to read with no special training or equipment required beyond the cup or device itself. All presumptive positive results from CLIA waived rapid tests should be confirmed by GC-MS or LC-MS/MS before any formal clinical, legal, or employment action is taken, consistent with standard point-of-care clinical testing protocols.
• OEM and Private Label CLIA Waived Fentanyl Drug Tests: Clinical Branding Support for Distributors and Healthcare Networks: Build your own branded CLIA waived fentanyl drug test product line with full OEM and private label support from 12 Panel Now. From custom logo and packaging to scalable wholesale manufacturing across cups, dip cards, and strip formats, we support clinical distributors, healthcare networks, laboratory supply companies, and pain management program operators building professionally branded CLIA waived testing products.
• Tiered Wholesale Pricing: Clinical-Grade Products at Competitive Cost Across All Formats: Our CLIA waived drug tests with fentanyl are priced competitively across all device types and panel counts. Tiered wholesale pricing scales with quantity. Send your current supplier's rate sheet to [email protected] and we will beat it by 10%.
• Deep US Inventory: Over 15 Million Units Across All CLIA Waived Fentanyl Products: Our US-based warehouse maintains deep standing inventory across all formats and panel counts in the CLIA waived fentanyl range at all times, ensuring no supply gaps, no backorder delays, and no fulfillment disruptions regardless of order volume.
• Same-Day Shipping on Every Order from Our US Warehouse: Every CLIA waived fentanyl drug test order ships the same day on orders placed before 3:00 PM EST. Free shipping is available on qualifying bulk purchases across all cup, dip card, strip, and analyzer formats.

Contact for OEM, Private Label and Bulk CLIA Waived Fentanyl Drug Test Orders: 561-897-9238  |  [email protected]